Literature DB >> 9024255

Effect of regional fat distribution and Prader-Willi syndrome on plasma leptin levels.

D S Weigle1, S L Ganter, J L Kuijper, D L Leonetti, E J Boyko, W Y Fujimoto.   

Abstract

Variability in the relationship of plasma leptin level to body mass index (BMI) could be caused by imperfect estimation of adipose mass by the BMI, heterogeneity in the pathogenesis of obesity in mixed subject groups, or variation in adipose tissue distribution. To investigate these possibilities, we examined the correlation of plasma leptin and BMI in an ethnically mixed population, a group of subjects with the Prader-Willi syndrome, and a group of Japanese-American subjects who underwent computerized tomographic measurement of adipose tissue cross-sectional areas. Highly significant and indistinguishable linear relationships between plasma leptin levels and BMI were found in the three study groups. Intersubject variability was also similar in the three groups and was reduced only when more accurate techniques for assessing adipose tissue mass were substituted for the BMI. The plasma leptin level of Japanese-American subjects in the highest quartile of intraabdominal fat area (mean area = 154.5 +/- 38.4 cm2) was 12.5 +/- 8.7 ng/mL as compared to 12.3 +/- 9.6 ng/mL (P = 0.91) for subjects in the lowest quartile of intraabdominal fat area (mean area = 51.2 +/- 20.1 cm2, P < 0.001 for difference in fat areas). We conclude that the circulating leptin level reflects total adipose tissue mass rather than a combination of adipose tissue mass and distribution, and that the Prader-Willi syndrome does not alter the relationship between these two variables.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9024255     DOI: 10.1210/jcem.82.2.3761

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Plasma leptin concentrations in lean and obese human subjects and Prader-Willi syndrome: comparison of RIA and ELISA methods.

Authors:  M G Carlson; W L Snead; A M Oeser; M G Butler
Journal:  J Lab Clin Med       Date:  1999-01

2.  Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial.

Authors:  Shawn E McCandless; Jack A Yanovski; Jennifer Miller; Cary Fu; Lynne M Bird; Parisa Salehi; Christine L Chan; Diane Stafford; M Jennifer Abuzzahab; David Viskochil; Sarah E Barlow; Moris Angulo; Susan E Myers; Barbara Y Whitman; Dennis Styne; Elizabeth Roof; Elisabeth M Dykens; Ann O Scheimann; Jaret Malloy; Dongliang Zhuang; Kristin Taylor; Thomas E Hughes; Dennis D Kim; Merlin G Butler
Journal:  Diabetes Obes Metab       Date:  2017-07-13       Impact factor: 6.577

3.  Are leptin levels dependent on body fat distribution in obese men and women?

Authors:  M Wauters; I Mertens; R Considine; I De Leeuw; L Van Gaal
Journal:  Eat Weight Disord       Date:  1998-09       Impact factor: 4.652

4.  Leptin levels recover normally in healthy older adults after acute diet-induced weight loss.

Authors:  M Yukawa; E A Phelan; H S Callahan; C F Spiekerman; I B Abrass; D S Weigle
Journal:  J Nutr Health Aging       Date:  2008-11       Impact factor: 4.075

5.  Association of cognitive restraint with ghrelin, leptin, and insulin levels in subjects who are not weight-reduced.

Authors:  Ellen A Schur; David E Cummings; Holly S Callahan; Karen E Foster-Schubert
Journal:  Physiol Behav       Date:  2007-11-23

Review 6.  Is there evidence that estrogen therapy promotes weight maintenance via effects on leptin?

Authors:  Alyse M Springer; Karen Foster-Schubert; Gregory J Morton; Ellen A Schur
Journal:  Menopause       Date:  2014-04       Impact factor: 2.953

7.  A transcriptomic approach to search for novel phenotypic regulators in McArdle disease.

Authors:  Gisela Nogales-Gadea; Inés Consuegra-García; Juan C Rubio; Joaquin Arenas; Marc Cuadros; Yolanda Camara; Javier Torres-Torronteras; Carmen Fiuza-Luces; Alejandro Lucia; Miguel A Martín; Elena García-Arumí; Antoni L Andreu
Journal:  PLoS One       Date:  2012-02-09       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.